Impact of 18F-DCFPyL-PSMA PET/CT on Radiotherapy Planning and Treatment Intensification in Occult Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
Abstract
Simple Summary Patients with prostate cancer (PC) may experience a rise in prostate-specific antigen (PSA) after radical prostatectomy (RP) despite having no detectable disease on conventional imaging. In this situation, treatment decisions are often based on clinical risk factors rather than the true location of recurrent disease. We evaluated whether 18F-DCFPyL prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) could better identify recurrent cancer and improve radiotherapy planning. In our prospective study, this imaging technique detected previously occult disease in more than half of the patients and led to substantial modifications in treatment strategy, including adaptation of radiotherapy target volumes, dose escalation, metastasis-directed stereotactic radiotherapy, systemic treatment intensification, or, in selected patients with negative scans, treatment de-escalation. These findings demonstrate that molecular imaging can support more personalized and precise salvage treatment, helping clinicians tailor radiotherapy according to the actual extent of recurrent disease rather than relying solely on conventional imaging or clinical risk factors.